Progress in Pherine Medications

Pherin Pharmaceuticals, Inc. (Pherin) is exclusively focused on the development of pherines for the treatment of human diseases and disorders.  To date, our technology has allowed us to make discoveries and file patents and patent applications that cover a large number of pherine molecules.  Our broad pipeline of products includes four lead compounds: Aloradine™ IN for acute treatment of Social Anxiety Disorder; PH10 nasal spray for acute treatment of Depression; Salubrin™ HF NS, for acute management of Menopausal Hot Flashes and other symptoms of menopause; PH10 nasal spray for ; and PH15 nasal spray for Cognitive Improvement. Pherin holds worldwide marketing rights to these compounds. We are open to discussions of collaborative licensing opportunities with forward-looking and technologically innovative pharmaceutical companies.

Product Pipeline

The results of a Phase 2B clinical study and a recently completed Phase 3 Feasibility study show significant and rapid clinical efficacy, excellent safety and benefits of the product Aloradine NS for the acute treatment of the symptoms of Social Anxiety Disorder. Pherin also conducted a Phase 2A clinical study to investigate the dosing regimen, product profile and proof of concept of the product PH10 nasal spray for the acute and PRN treatment of Depression, and Salubrin-HF for the acute management of Menopausal Hot Flashes. Also completed is a Phase 2B clinical efficacy and safety study of PH80-PMD for the treatment of Premenstrual Dysphoric Disorder.

Numerous Therapeutic Advantages
Pherine compounds are directly delivered to the nasal passages using a metered nasal spray. By virtue of the direct connections to the hypothalamus and limbic system and the ability of our compounds to act locally, pherines do not need to achieve systemic absorption and distribution. This provides a significant therapeutic advantage over traditional therapeutics targeted at the hypothalamus and limbic system that require access to systemic circulation and must cross the blood-brain barrier, followed by uptake into the brain to exert effects.

We believe the unique mechanism of action and method of delivery of pherines results in numerous therapeutic advantages.

Properties of Pherines

The term pherines refers to odorless substances that have pharmacological effect as a consequence of binding to specific peripheral receptors in the nasal passages.

  • Act locally
  • Rapid onset of effect
  • Systemic absorption not required
  • Active in ultra low dosages (nanograms)
  • Excellent safety profile and tolerability
Development Programs

Social Anxiety Disorder - The term Social Anxiety Disorder describes a collection of disorders that share many similar clinical features and treatment strategies.

Depression - Depression is a mood disorder characterized by extreme and persistent disruption of a person’s usual emotional state, affecting physical health as well as how the sufferer feels, thinks and behaves toward others.

Menopausal Hot Flashes - Hot flashes are the most common symptom of menopause. In the USA approximately 40 million women are at or near menopause with some 45 million being beyond menopause.

Cognition Improvement - Cognitive deficits are characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stability that can gradually lead to profound mental deterioration.